Patents by Inventor Stephane De Lombaert

Stephane De Lombaert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS OF AN S1P-RECEPTOR MODULATOR
    Publication number: 20230339967
    Abstract: This application relates to solid forms of an S1P-receptor modulator, which are useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 26, 2023
    Inventors: Stéphane De Lombaert, Ana Rosario Mollo Sarno, Michael A. Christie, Edward L. Ciolkowski, Susana del Rio Gancedo, Joseph Stephen Harris, Lucy Kristina Mapp, Mateusz Bogumil Pitak, Scott L. Childs
  • Spirocyclic compounds as tryptophan hydroxylase inhibitors
    Patent number: 11759462
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: September 19, 2023
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Processes for preparing TPH1 inhibitors
    Patent number: 11708365
    Abstract: The present disclosure is directed to intermediates and salts thereof useful for the preparation of spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1). Processes of preparing the intermediates, salts, and TPH inhibitors are also provided.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: July 25, 2023
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg
  • INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS
    Publication number: 20230077268
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: May 11, 2022
    Publication date: March 9, 2023
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Jacob Bradley Schwarz, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • Solid forms of an S1P-receptor modulator
    Patent number: 11535632
    Abstract: This application relates to solid forms of an S1P-receptor modulator, which are useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 27, 2022
    Assignee: ESCAPE Bio, Inc.
    Inventors: Stéphane De Lombaert, Ana Rosario Mool Sarno, Michael A. Christie, Edward L. Ciolkowski, Susana del Rio Gancedo, Joseph Stephen Harris, Lucy Kristina Mapp, Mateusz Bogumil Pitak, Scott L. Childs
  • Indazoles and azaindazoles as LRRK2 inhibitors
    Patent number: 11427558
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: August 30, 2022
    Assignee: ESCAPE Bio, Inc.
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Jacob Bradley Schwarz, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • INDAZOLES AS LRRK2 INHIBITORS
    Publication number: 20220162192
    Abstract: The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 26, 2022
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
    Publication number: 20210205305
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: March 15, 2021
    Publication date: July 8, 2021
    Applicant: Altavant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • SOLID FORMS OF AN S1P-RECEPTOR MODULATOR
    Publication number: 20210139502
    Abstract: This application relates to solid forms of an S1P-receptor modulator, which are useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders.
    Type: Application
    Filed: October 30, 2020
    Publication date: May 13, 2021
    Inventors: Stéphane De Lombaert, Ana Rosario Mollo Sarno, Michael A. Christie, Edward L. Ciolkowski, Susana del Rio Gancedo, Joseph Stephen Harris, Lucy Kristina Mapp, Mateusz Bogumil Pitak, Scott L. Childs
  • PROCESSES FOR PREPARING AN S1P-RECEPTOR MODULATOR
    Publication number: 20210139503
    Abstract: This application relates to processes for preparing an S1P-receptor modulator, which is useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders.
    Type: Application
    Filed: October 30, 2020
    Publication date: May 13, 2021
    Inventors: Stéphane De Lombaert, Jonathon Daryll Schwarz Holt, Ana Rosario Mollo Sarno, Jacob Bradley Schwarz, Michael A. Christie, Edward L. Ciolkowski, Zenghong Zhang
  • PROCESSES FOR PREPARING TPH1 INHIBITORS
    Publication number: 20210139481
    Abstract: The present disclosure is directed to intermediates and salts thereof useful for the preparation of spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1). Processes of preparing the intermediates, salts, and TPH inhibitors are also provided.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 13, 2021
    Applicant: ALTAVANT SCIENCES GmbH
    Inventors: STÉPHANE DE LOMBAERT, DANIEL R. GOLDBERG
  • Spirocyclic compounds as tryptophan hydroxylase inhibitors
    Patent number: 10946018
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: March 16, 2021
    Assignee: Roivant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
    Publication number: 20200237760
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: April 16, 2020
    Publication date: July 30, 2020
    Applicant: Roivant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Processes for preparing (R)-1-(5-chloro-[1,1?-biphenyl] -2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethanone
    Patent number: 10710948
    Abstract: The present invention relates to processes for the preparation of (R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethanol, 1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethanone, and intermediates thereof, which are useful in the preparation of inhibitors of TPH1 for the treatment of, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, low bone mass diseases, serotonin syndrome, and cancer.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: July 14, 2020
    Assignee: Roivant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg
  • Spirocyclic compounds as tryptophan hydroxylase inhibitors
    Patent number: 10660893
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: May 26, 2020
    Assignee: ROIVANT SCIENCES, GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • PROCESSES FOR PREPARING (R)-1-(5-CHLORO-[1,1'-BIPHENYL]-2-YL)-2,2,2-TRIFLUOROETHANOL AND 1-(5- CHLORO-[1,1'-BIPHENYL]-2-YL)-2,2,2-TRIFLUOROETHANONE
    Publication number: 20190375699
    Abstract: The present invention relates to processes for the preparation of (R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethanol, 1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethanone, and intermediates thereof, which are useful in the preparation of inhibitors of TPH1 for the treatment of, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, low bone mass diseases, serotonin syndrome, and cancer.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 12, 2019
    Applicant: Roivant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg
  • SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
    Publication number: 20190282575
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: May 30, 2019
    Publication date: September 19, 2019
    Applicant: Altavant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • PROCESSES FOR PREPARING TPH1 INHIBITORS
    Publication number: 20190263815
    Abstract: The present disclosure is directed to intermediates and salts thereof useful for the preparation of spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH 1). Processes of preparing the intermediates, salts, and TPH inhibitors are also provided.
    Type: Application
    Filed: May 9, 2019
    Publication date: August 29, 2019
    Applicant: ALTAVANT SCIENCES GmbH
    Inventors: STÉPHANE DE LOMBAERT, DANIEL R. GOLDBERG
  • Spirocyclic compounds as tryptophan hydroxylase inhibitors
    Patent number: 10350208
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: July 16, 2019
    Assignee: Roivant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
    Publication number: 20180256574
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: May 14, 2018
    Publication date: September 13, 2018
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner